Comparative Pharmacology
Head-to-head clinical analysis: R P MYCIN versus ZMAX.
Peer-Reviewed Evidence
Head-to-head clinical analysis: R P MYCIN versus ZMAX.
R-P MYCIN vs ZMAX
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
R-P MYCIN is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S subunit of the bacterial ribosome, specifically at the 23S rRNA of the peptidyl transferase center. This action blocks the translocation step, thereby preventing the elongation of the peptide chain.
Azithromycin, the active ingredient in ZMAX, is a macrolide antibiotic that binds to the 50S ribosomal subunit of susceptible bacteria, inhibiting protein synthesis and bacterial growth.
Rifampin 600 mg orally once daily or 10 mg/kg intravenously once daily.
500 mg orally once daily, administered as a single dose on an empty stomach.
None Documented
None Documented
Terminal half-life 2-3 hours; prolonged in renal impairment (up to 6-8 hours in anuria).
Terminal half-life: 68 hours (range 40-80 h); prolonged in hepatic impairment (up to 120 h) and elderly; supports once-weekly dosing.
Renal (60-80% unchanged), biliary/fecal (15-20%).
Renal: ~20% unchanged; fecal: ~50% as metabolites; biliary: ~30% as metabolites and parent drug.
Category C
Category C
Macrolide Antibiotic
Macrolide Antibiotic